You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday.
Over the last year, Katie dove into the science and business of continuous glucose monitors. For a comprehensive look at what’s ahead for the devices — not just for diabetes patients, but the broader public — grab a copy of our new STAT Report.
Biosensors at three-letter conferences
advertisement
Speaking of CGM, device maker Dexcom’s presentation at this week’s all-virtual JP Morgan Healthcare Conference finally showed forward movement on its next-generation continuous glucose monitor, the G7. The company filed with the FDA in late 2021, and shared data from its submission at JPM, including results showing that the device meets the standards to feed its data into automated insulin pumps. “Our current systems have been designed to readily connect with the automated insulin delivery developments that are going to be coming out over the next several years,” said CEO Kevin Sayer. “I would even go so far as to say sharing data may be one of the most significant innovations this company has done over its history.”
The news comes as Dexcom’s primary competitor Abbott made a bold announcement last week at CES: The company will launch a new line of disposable direct-to-consumer biosensors dubbed Lingo. The first device will measure ketones, targeting fans of the faddish keto diet, although observers suggest such sensing could be an attractive addition for patients who diligently track their numbers to avoid diabetic ketoacidosis. The company also plans consumer glucose and lactate biosensors, aimed at helping people optimize nutrition and exercise. As glucose monitoring companies aim to scoop up an increasingly broad user base, Dexcom may have to decide whether it will focus on making the best possible product for people with diabetes, or reaching the biggest possible market by bringing in a new generation of sensor-happy users.
advertisement
In other news at JPM…
- Teladoc nudged revenue projections for the 2021 fiscal year up slightly to $2.03 billion, as CEO Jason Gorevic doubled down on the company’s vision for “whole person care”: virtually treating patients’ mental, physical, chronic and complex needs and connecting them to brick-and-mortar services when needed.
- Executives with Oak Street Health, a provider of virtual and in-person primary care to Medicare patients, said they will open the throttle on their expansion plans in 2022, adding 70 new …….
Source: https://www.statnews.com/2022/01/11/health-tech-jpm-acquisitions/